Heron Therapeuti
$ 1.17
-7.87%
11 Feb - close price
- Market Cap 232,870,000 USD
- Current Price $ 1.17
- High / Low $ 1.26 / 1.17
- Stock P/E N/A
- Book Value 0.04
- EPS -0.09
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE -24.09 %
- 52 Week High 2.68
- 52 Week Low 1.00
About
Heron Therapeutics, Inc. (HRTX), headquartered in San Diego, California, is a pioneering biotechnology firm focused on developing innovative therapies for unmet medical needs in pain management and antiemetic care. The company is dedicated to optimizing patient outcomes through its robust pipeline of advanced pharmaceutical solutions, specifically tailored for individuals undergoing surgical procedures and cancer treatments. With a strong emphasis on addressing high-demand therapeutic areas, Heron Therapeutics is well-positioned to drive significant advancements in healthcare, thereby enhancing the quality of life for patients and addressing critical challenges within the medical community.
Analyst Target Price
$4.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-08 | 2025-05-05 | 2025-03-10 | 2024-11-12 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-14 | 2023-08-14 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -0.1 | -0.02 | 0.0134 | 0.02 | -0.0317 | -0.06 | -0.02 | -0.07 | -0.17 | -0.35 | -0.27 | -0.17 |
| Estimated EPS | -0.01 | -0.01 | -0.01 | -0.025 | -0.03 | -0.04 | -0.09 | -0.16 | -0.29 | -0.23 | -0.2 | -0.28 |
| Surprise | -0.09 | -0.01 | 0.0234 | 0.045 | -0.0017 | -0.02 | 0.07 | 0.09 | 0.12 | -0.12 | -0.07 | 0.11 |
| Surprise Percentage | -900% | -100% | 234% | 180% | -5.6667% | -50% | 77.7778% | 56.25% | 41.3793% | -52.1739% | -35% | 39.2857% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HRTX
2026-02-09 02:29:41
The New York State Common Retirement Fund significantly increased its stake in Heron Therapeutics, Inc. (HRTX) by 46.4% in the third quarter, acquiring 816,671 additional shares to hold a total of 2,576,716 shares valued at $3.25 million. Other institutional investors also adjusted their positions in the biotechnology company. Heron Therapeutics currently trades near its 52-week low, and analysts have an average "Hold" rating with a target price of $4.50.
2026-01-30 04:31:25
Heron Therapeutics, Inc. (HRTX) is attracting investor interest with analysts projecting a 238.35% upside potential, setting an average target price of $4.50. The biotechnology company, specializing in therapeutic solutions using its Biochronomer technology, shows positive revenue growth despite current financial challenges like negative EPS and free cash flow. While the stock's technical indicators are neutral, strong analyst sentiment with all "buy" ratings suggests optimism for its diverse product pipeline and market expansion.
2026-01-27 16:30:08
Heron Therapeutics (NASDAQ:HRTX) stock recently passed above its 200-day moving average, a technical breakout, despite mixed analyst ratings with an average price target of $4.50. The company reported a quarterly EPS loss that missed expectations and slightly lower revenue. Institutional and hedge fund ownership of the stock is significant, holding approximately 80% of shares.
2026-01-18 09:57:31
Five analysts have issued an average "Hold" recommendation for Heron Therapeutics (NASDAQ:HRTX), with an average 1-year price target of $4.50. Despite significant institutional investment, including Clearline Capital increasing its stake by 1,033%, the company's near-term fundamentals appear weak, marked by a recent EPS miss and a negative P/E ratio. Shares currently trade around $1.49, falling within a 12-month range of $1.00 to $2.68.
2026-01-13 20:27:32
This article provides an update on Heron's financial performance, noting that preliminary revenue figures have exceeded estimates. This positive news has led to an increase in the company's standing.
2026-01-12 10:27:53
Heron Therapeutics, Inc. (NASDAQ:HRTX) saw a 10% stock gain last week, which is welcomed by its institutional investors, who hold a significant 57% stake in the company. Hedge funds own 27% with Rubric Capital Management LP as the largest shareholder at 16%. The general public holds 15%, while insiders own less than 1% of the US$255 million market cap company.
